Compare PGY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | TBPH |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | 518 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.3M | 824.9M |
| IPO Year | N/A | 2013 |
| Metric | PGY | TBPH |
|---|---|---|
| Price | $14.17 | $16.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $34.50 | $18.40 |
| AVG Volume (30 Days) | ★ 2.8M | 473.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $14.96 | $1.04 |
| Revenue Next Year | $13.97 | N/A |
| P/E Ratio | $13.54 | ★ $8.08 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.95 | $8.33 |
| 52 Week High | $44.99 | $21.03 |
| Indicator | PGY | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.77 | 59.16 |
| Support Level | $10.58 | $13.41 |
| Resistance Level | $25.47 | $19.04 |
| Average True Range (ATR) | 0.76 | 0.52 |
| MACD | 0.35 | 0.22 |
| Stochastic Oscillator | 98.96 | 83.84 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.